Durvalumab Plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer(CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial

WU Yu-wei; ZHAO Min-fang; KE E-e

doi:10.12019/j.issn.1671-5144.2020.03.007

WU Yu-wei, ZHAO Min-fang, KE E-e. Durvalumab Plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer(CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial[J]. Journal of Evidence-Based Medicine, 2020, 20(3): 158-162. DOI: 10.12019/j.issn.1671-5144.2020.03.007

Citation:

WU Yu-wei, ZHAO Min-fang, KE E-e. Durvalumab Plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer(CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial[J]. Journal of Evidence-Based Medicine, 2020, 20(3): 158-162. DOI: 10.12019/j.issn.1671-5144.2020.03.007

Citation:

WU Yu-wei, ZHAO Min-fang, KE E-e. Durvalumab Plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer(CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial[J]. Journal of Evidence-Based Medicine, 2020, 20(3): 158-162. DOI: 10.12019/j.issn.1671-5144.2020.03.007

Durvalumab Plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer(CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial

Graphical Abstract

Abstract

FullText(HTML)

References (6)

Durvalumab Plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer(CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial

Catalog

Export File

Citation

Format

Content